Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany.
The Company is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. Amanitin is a member of the amatoxin group of natural poisons, which includes the death cap mushroom (Amanita phalloides). Amanitin inhibits RNA polymerase II which results in programmed cell death (apoptosis). Using an Antibody Drug Conjugate (ADC) technology, this highly effective agent Amanitin will be coupled via a chemical linker with different antibodies. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates.
The lead candidate HDP-101 is a BCMA-ATAC in clinical development for multiple myeloma. Further ATAC candidates are being developed against different targets such as CD37, PSMA or GCC each in the indications non-Hodgkin’s lymphoma, metastatic castration-resistant prostate cancer or gastrointestinal tumors such as colorectal cancer.
Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at